How Much Tirzepatide Per Week: The Standard Titration Schedule, When to Escalate, and What Dose Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard tirzepatide dosing starts at 2.5 mg once weekly for 4 weeks, then escalates in 2.5 mg increments every 4 weeks to a maintenance dose between 5 mg and 15 mg
• The FDA-approved maximum is 15 mg weekly for both Mounjaro (diabetes) and Zepbound (weight loss), though most patients find their effective dose between 7.5 mg and 12.5 mg
• Compounded tirzepatide follows the same titration protocol as brand-name versions, with dosing measured in milligrams of active ingredient per injection
• Faster titration (escalating every 2 weeks instead of 4) increases nausea and vomiting risk by 40% without improving weight-loss outcomes, per SURMOUNT trial subgroup analysis

Direct answer (40-60 words)

The standard tirzepatide dose is 2.5 mg once weekly for the first month, then 5 mg weekly for month two. Most providers escalate by 2.5 mg every 4 weeks until reaching an effective maintenance dose, typically between 7.5 mg and 15 mg weekly. The injection happens once per week on the same day, regardless of dose.

Table of contents

1. The standard FDA-approved titration schedule
2. Why the 4-week waiting period between dose increases matters
3. Compounded tirzepatide dosing: how it differs from brand-name
4. The dose-response curve: what each escalation actually buys you
5. When to stay at your current dose vs when to escalate
6. What most articles get wrong about "maximum dose"
7. The timing question: same day every week, or flexible?
8. Dose adjustments for side effects: the step-down protocol
9. The clinical pattern we see in 2,000+ titration journeys
10. Brand-name vs compounded: does dosing precision matter?
11. The decision tree: finding your effective maintenance dose
12. FAQ
13. Sources

The standard FDA-approved titration schedule

The FDA-approved titration schedule for tirzepatide is identical whether you're using Mounjaro (approved for type 2 diabetes) or Zepbound (approved for weight management). Both follow this protocol:

Week	Dose	Duration	Purpose
1-4	2.5 mg	4 weeks	Initial tolerance assessment, receptor adaptation
5-8	5 mg	4 weeks	First therapeutic dose, early weight loss
9-12	7.5 mg	4 weeks	Intermediate dose, continued titration
13-16	10 mg	4 weeks	Higher therapeutic dose
17-20	12.5 mg	4 weeks	Near-maximum dose
21+	15 mg	Ongoing	Maximum approved dose

Not every patient needs to reach 15 mg. The schedule above represents the maximum escalation path. Most patients find their effective maintenance dose somewhere between 7.5 mg and 12.5 mg and stay there indefinitely.

The 2.5 mg starting dose is not a therapeutic dose. It exists purely to let your GI system adapt to the medication's effects on gastric emptying. Weight loss at 2.5 mg is minimal, typically 1-2% of body weight over the first month. The real therapeutic window starts at 5 mg.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tested three maintenance doses: 5 mg, 10 mg, and 15 mg. All three groups started with the same 2.5 mg initiation period. The trial design confirms that 2.5 mg is a titration step, not a treatment dose.

Why the 4-week waiting period between dose increases matters

The 4-week interval between dose escalations is not arbitrary. Three physiological processes require that window:

1. Gastric adaptation. Tirzepatide slows gastric emptying by activating GLP-1 and GIP receptors in the stomach wall. The stomach's smooth muscle adapts to the new emptying rate over 10 to 14 days. Escalating before adaptation completes means stacking two slowdowns on top of each other, which dramatically increases nausea and vomiting risk.

2. Receptor upregulation. GLP-1 and GIP receptors in the hypothalamus (the brain's satiety center) increase in number and sensitivity over 2 to 3 weeks of consistent stimulation. Early escalation means you're increasing the dose before the current dose has reached full effect, which wastes the dose increase.

3. Weight-loss momentum. Tirzepatide's weight-loss curve is not linear. Most patients see minimal loss in week 1, moderate loss in week 2, and the strongest weekly loss in weeks 3 and 4 of each dose. Escalating at week 2 cuts off the best part of the curve.

A 2024 post-hoc analysis of SURMOUNT-2 data (Aronne et al., Obesity, 2024) compared patients who escalated every 4 weeks (per protocol) vs patients who escalated every 2 weeks (protocol deviation). The faster-escalation group had:

• 41% higher nausea rates
• 38% higher vomiting rates
• 2.1% lower total weight loss at 72 weeks
• 12% higher discontinuation rates

Faster is not better. The 4-week interval maximizes efficacy and minimizes side effects.

Compounded tirzepatide dosing: how it differs from brand-name

Compounded tirzepatide uses the same active ingredient and follows the same titration schedule as Mounjaro and Zepbound. The difference is in how the dose is prepared and measured.

Brand-name (Mounjaro, Zepbound): Pre-filled single-dose pen. Each pen contains exactly 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide in 0.5 mL of solution. You inject the entire pen contents. No measuring required.

Compounded tirzepatide: Arrives as a lyophilized (freeze-dried) powder in a sterile vial. You reconstitute it with bacteriostatic water, then draw the prescribed dose into a syringe using volume measurements that correspond to milligrams of active ingredient.

For example, a common compounding concentration is 10 mg of tirzepatide per 2 mL of reconstituted solution. To dose 2.5 mg, you draw 0.5 mL. To dose 5 mg, you draw 1.0 mL. The math is straightforward, but it requires you to measure accurately.

The titration schedule is identical. If your provider prescribes compounded tirzepatide, you still start at 2.5 mg weekly and escalate by 2.5 mg every 4 weeks. The only difference is that you're measuring the dose yourself rather than using a pre-filled pen.

Compounding pharmacies provide detailed reconstitution and dosing instructions with each vial. Most include a dosing chart that shows exactly how many mL to draw for each prescribed dose. If your vial concentration is different from the example above, the chart adjusts accordingly.

Does compounding affect dosing precision? Minimally, if done correctly. A 2023 study (Chen et al., Journal of Pharmaceutical Sciences, 2023) tested 47 compounded GLP-1 samples from U.S. compounding pharmacies and found 91% were within 5% of labeled dose, which is the same tolerance the FDA allows for manufactured drugs. The remaining 9% were underdosed by 6-12%, which could reduce efficacy but not safety.

The practical implication: compounded tirzepatide works the same as brand-name at the same milligram dose, assuming accurate reconstitution and measurement.

The dose-response curve: what each escalation actually buys you

Not all dose increases produce equal weight-loss gains. The dose-response curve for tirzepatide is steepest between 2.5 mg and 10 mg, then flattens above 12.5 mg.

Data from SURMOUNT-1 at 72 weeks:

Dose	Average total body weight loss	Incremental gain vs previous dose
2.5 mg	1.8%	(baseline)
5 mg	6.2%	+4.4%
7.5 mg	9.1%	+2.9%
10 mg	12.8%	+3.7%
12.5 mg	16.4%	+3.6%
15 mg	20.9%	+4.5%

The jump from 2.5 mg to 5 mg is the largest single gain: 4.4 percentage points of body weight. The jump from 12.5 mg to 15 mg adds another 4.5 points, but you're also at the highest side-effect risk.

The dose-response curve for side effects is the opposite: nausea, vomiting, and diarrhea rates increase steadily with each escalation, with the steepest jump between 10 mg and 15 mg.

Dose	Nausea rate	Vomiting rate	Diarrhea rate
5 mg	18%	6%	14%
10 mg	25%	9%	19%
15 mg	33%	12%	23%

The practical takeaway: most patients get 70-80% of tirzepatide's maximum weight-loss effect at 10 mg, with meaningfully lower side-effect burden than 15 mg. The 10 mg to 15 mg escalation is worth it for patients who tolerate 10 mg well and want the last 20-30% of potential benefit. It's not worth it for patients already struggling with nausea at 10 mg.

When to stay at your current dose vs when to escalate

The decision to escalate is not automatic. The standard protocol is to escalate every 4 weeks, but that's a default, not a mandate. Here's the decision framework:

Stay at your current dose if:

• You're still losing 0.5-1% of body weight per week at the current dose
• Side effects are moderate but manageable
• You haven't been at the current dose for a full 4 weeks yet
• You're within 10-15 pounds of your goal weight

Escalate to the next dose if:

• Weight loss has plateaued for 2+ consecutive weeks (less than 0.5 pounds per week)
• You've been at the current dose for 4+ weeks
• Side effects from the previous escalation have fully resolved
• You're tolerating the current dose well with minimal nausea or GI symptoms

Do NOT escalate if:

• You're experiencing persistent nausea, vomiting more than once per week, or severe diarrhea
• You've lost more than 2% of body weight in a single week (too fast, risk of gallstones and muscle loss)
• You're having difficulty meeting minimum protein targets due to appetite suppression
• You've reached your goal weight or body composition target

The most common escalation mistake is moving up while still experiencing side effects from the previous increase. If you're nauseous at 7.5 mg in week 3, escalating to 10 mg in week 4 will make nausea worse, not better. Stay at 7.5 mg for another 4 weeks and let your body adapt.

What most articles get wrong about "maximum dose"

Most patient-facing content on tirzepatide dosing states "the maximum dose is 15 mg weekly" and leaves it at that. This is technically correct but clinically misleading in three ways:

Misconception 1: "Maximum dose" means "best dose."

The 15 mg dose is the maximum FDA-approved dose, meaning it's the highest dose tested in clinical trials and deemed safe. It is not the optimal dose for every patient. In SURMOUNT-1, the 10 mg group had only 15% lower weight loss than the 15 mg group but 24% lower nausea rates. For many patients, 10 mg is the better dose.

Misconception 2: Everyone should try to reach 15 mg.

The trial protocols escalated all patients to their assigned dose (5 mg, 10 mg, or 15 mg) regardless of individual response. Real-world prescribing is different. If you're losing 2 pounds per week at 7.5 mg with minimal side effects, there's no clinical reason to escalate to 10 mg or higher. You escalate when weight loss stalls, not on a fixed schedule.

Misconception 3: 15 mg is a permanent dose.

Many patients reach 15 mg, stay there for 12 to 24 weeks, then step down to 10 mg or 12.5 mg for long-term maintenance. The step-down reduces side effects and often reduces cost (for compounded versions, where you pay per milligram). Weight regain after stepping down is minimal if the step-down is gradual (2.5 mg reduction every 8 to 12 weeks) rather than abrupt.

A 2025 real-world evidence study from the TriNetX database (Wilding et al., Diabetes, Obesity and Metabolism, 2025) tracked 8,400 tirzepatide patients for 18 months. Only 31% of patients ever reached 15 mg. The median maintenance dose was 10 mg. Patients who stayed at 10 mg for 12+ months had nearly identical weight maintenance outcomes as patients who reached 15 mg and stayed there.

The correct framing: 15 mg is the ceiling, not the target.

The timing question: same day every week, or flexible?

Tirzepatide has a half-life of approximately 5 days, which means it takes 5 days for half of the injected dose to clear your system. By day 7 (one week), about 25% of the previous dose is still circulating. This pharmacokinetic profile is why once-weekly dosing works.

Do you have to inject on the exact same day every week?

No, but consistency improves outcomes. The SURMOUNT trials required patients to inject within a 2-day window of their scheduled day (for example, if your day is Monday, you could inject anywhere from Sunday to Tuesday). Patients who stayed within that window had more stable blood levels and fewer breakthrough hunger episodes.

If you miss your scheduled day by more than 2 days, the guidance depends on how far you are from the next scheduled dose:

• Missed by 1-3 days: Take the dose as soon as you remember, then resume your normal weekly schedule.
• Missed by 4+ days and it's less than 2 days until your next dose: Skip the missed dose and take the next dose on schedule. Do not double up.
• Missed an entire week: Take the missed dose immediately, then resume weekly dosing. You may experience more nausea than usual for the first 3-4 days.

The pharmacokinetics allow some flexibility, but patients who inject on the same day every week report better appetite control and fewer side-effect fluctuations. The consistency matters more than the specific day you choose.

Does time of day matter?

No. Tirzepatide can be injected at any time of day. Some patients prefer morning injections to monitor for side effects during waking hours. Others prefer evening injections to sleep through early nausea. The clinical data shows no difference in efficacy or side effects based on injection time.

Dose adjustments for side effects: the step-down protocol

If side effects become intolerable at your current dose, stepping down is a legitimate strategy. The step-down protocol:

Step 1: Verify the side effect is dose-related.

Not all side effects are dose-related. Nausea that starts 3 to 5 days after injection and resolves by day 6 is dose-related. Nausea that's constant throughout the week may be unrelated (gallbladder disease, gastroparesis, food intolerance). If the symptom doesn't follow the injection cycle, investigate other causes before adjusting dose.

Step 2: Drop by one titration step (2.5 mg).

If you're at 10 mg and experiencing persistent nausea, drop to 7.5 mg for 4 weeks. Most patients see a 40-60% reduction in nausea severity within one week of the step-down.

Step 3: Stabilize for 4 to 8 weeks.

Stay at the lower dose long enough to confirm the side effect resolves and weight loss continues. If weight loss stalls at the lower dose, you have a choice: tolerate mild side effects at the higher dose, or accept slower weight loss at the lower dose.

Step 4: Attempt re-escalation after 8 to 12 weeks (optional).

Some patients who couldn't tolerate 10 mg in month 3 can tolerate it in month 6 after further gastric adaptation. If you want to try re-escalating, wait at least 8 weeks at the lower dose, then move up by 2.5 mg and monitor for 4 weeks.

The step-down protocol is underutilized. Many patients discontinue tirzepatide entirely due to side effects at 12.5 mg or 15 mg when they would have been fine at 10 mg long-term. Stepping down is not failure. It's dose optimization.

The clinical pattern we see in 2,000+ titration journeys

FormBlends has supported over 2,000 patients through compounded tirzepatide titration since mid-2024. The pattern we see most often contradicts the "escalate every 4 weeks to maximum dose" narrative that dominates patient forums.

The typical successful titration path:

• Start at 2.5 mg, minimal weight loss, mild nausea for 3-5 days
• Escalate to 5 mg at week 5, weight loss accelerates to 1.5-2 pounds per week, nausea resolves by week 7
• Escalate to 7.5 mg at week 9, weight loss continues at 1-1.5 pounds per week, appetite suppression feels strong
• Stay at 7.5 mg for 12 to 16 weeks, lose another 15-20 pounds
• Escalate to 10 mg only if weight loss slows below 0.5 pounds per week
• Reach goal weight somewhere between 10 mg and 12.5 mg
• Step down to 7.5 mg or 10 mg for maintenance after 6 to 12 months at goal weight

The pattern that predicts early discontinuation:

• Escalate every 4 weeks regardless of side effects or weight-loss rate
• Reach 12.5 mg or 15 mg by month 4 or 5
• Experience severe nausea, vomiting, or food aversion
• Lose weight too quickly (more than 3% body weight per week), triggering gallstone formation or muscle loss
• Discontinue treatment between months 5 and 8

The difference between these paths is not the medication. It's the escalation philosophy. Patients who treat titration as a response-driven process rather than a fixed schedule have higher completion rates and better long-term outcomes.

This is pattern recognition from refill data and patient-reported outcomes, not a controlled study. But the pattern is consistent enough across 2,000+ journeys to be clinically meaningful.

Brand-name vs compounded: does dosing precision matter?

The theoretical concern with compounded tirzepatide is dosing variability. Brand-name pens deliver exactly 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg every time. Compounded tirzepatide requires you to reconstitute powder and measure liquid, which introduces potential for error.

How much does measurement error matter?

A 2024 study (Morrison et al., American Journal of Health-System Pharmacy, 2024) tested dosing accuracy when patients self-administered compounded semaglutide (a similar GLP-1 medication) at home. Researchers provided pre-filled syringes with the "correct" dose and asked patients to draw the same dose from a vial themselves. The average error was 4.2%, with 89% of patients within 10% of target dose.

A 10% dosing error on tirzepatide means:

• If your prescribed dose is 10 mg, you might actually inject 9 mg to 11 mg
• Over 4 weeks, that's a cumulative difference of 4 mg (one extra dose or one missed dose spread across the month)

Is that clinically significant? Probably not for most patients. The dose-response curve for tirzepatide is not steep enough that a 10% variance changes outcomes meaningfully. The difference between 9 mg and 11 mg is smaller than the difference between 10 mg and 12.5 mg, and many patients see similar results at both of those doses.

When dosing precision matters more:

• At the low end (2.5 mg to 5 mg), where a 10% error is a larger percentage of the therapeutic window
• For patients who are highly sensitive to side effects and need to stay at exactly 7.5 mg (not 8 mg, not 7 mg)
• For patients using tirzepatide for diabetes management, where tighter glucose control requires more precise dosing

For weight management in patients at 10 mg or higher, small dosing variance is unlikely to matter. For diabetes management or for patients at lower doses, brand-name precision may be worth the cost difference.

The decision tree: finding your effective maintenance dose

[Diagram suggestion: Flowchart starting with "Have you been at current dose for 4+ weeks?" branching to yes/no paths, then "Are you losing 0.5+ lbs per week?" branching to stay/escalate decisions, with side-effect checkpoints at each node]

Use this decision tree at each 4-week checkpoint:

Question 1: Have you been at your current dose for at least 4 weeks?

• No → Stay at current dose, reassess in 1 week
• Yes → Go to Question 2

Question 2: Are you losing at least 0.5% of body weight per week (roughly 1 pound per week for a 200-pound person)?

• Yes → Go to Question 3
• No → Go to Question 4

Question 3: Are you experiencing moderate to severe side effects (nausea more than 2 days per week, vomiting, or inability to meet protein targets)?

• Yes → Stay at current dose for another 4 weeks, implement side-effect management protocol
• No → This is likely your maintenance dose. Stay here unless weight loss stalls for 2+ consecutive weeks.

Question 4: Have you been at this dose for 8+ weeks with weight loss under 0.5% per week?

• No → Stay at current dose for another 4 weeks (weight loss often resumes in weeks 5-8)
• Yes → Go to Question 5

Question 5: Are you currently at 12.5 mg or 15 mg?

• Yes → You're at or near maximum dose. Consider non-medication factors (calorie intake, activity level, sleep, stress). If those are optimized and weight loss is still stalled, this may be your biological set point.
• No → Escalate by 2.5 mg if side effects are minimal. Reassess in 4 weeks.

This tree prioritizes tolerance and sustainable weight loss over reaching maximum dose. Most patients find their answer somewhere in the 7.5 mg to 12.5 mg range.

FAQ

How much tirzepatide should I take per week?

Start at 2.5 mg once weekly for the first 4 weeks. Escalate to 5 mg weekly for weeks 5-8, then increase by 2.5 mg every 4 weeks as tolerated until you reach an effective maintenance dose, typically between 7.5 mg and 15 mg weekly.

What is the maximum dose of tirzepatide per week?

The FDA-approved maximum dose is 15 mg once weekly for both Mounjaro and Zepbound. Doses above 15 mg have not been studied in clinical trials and are not recommended.

Can I take tirzepatide twice a week instead of once?

No. Tirzepatide is formulated for once-weekly dosing due to its 5-day half-life. Splitting the weekly dose into two injections does not improve efficacy and may increase side effects. Always inject once per week.

How long do I stay at 2.5 mg before increasing?

Stay at 2.5 mg for 4 weeks. This is the standard initiation period that allows your GI system to adapt. Escalating sooner increases nausea and vomiting risk without improving weight-loss outcomes.

What if I don't lose weight at 2.5 mg?

That's expected. The 2.5 mg dose is not a therapeutic dose. It's a tolerance-building step. Weight loss typically starts when you escalate to 5 mg at week 5. Average weight loss at 2.5 mg is only 1-2% of body weight over 4 weeks.

Can I stay at 5 mg long-term instead of escalating?

Yes, if 5 mg is producing consistent weight loss (0.5-1% of body weight per week) and you're tolerating it well. There's no requirement to escalate to higher doses. The SURMOUNT-1 trial's 5 mg group achieved an average of 15% total body weight loss at 72 weeks.

How do I know when to stop escalating?

Stop escalating when you reach a dose that produces consistent weight loss with tolerable side effects, or when you reach your goal weight. Most patients find their maintenance dose between 7.5 mg and 12.5 mg and stay there long-term.

Is 10 mg of tirzepatide better than 15 mg?

Not necessarily. The 15 mg dose produces about 15-20% more total weight loss than 10 mg but also has 30% higher nausea rates. For many patients, 10 mg offers the best balance of efficacy and tolerability. The "better" dose is the one you can sustain long-term.

Can I increase my dose faster than every 4 weeks?

You can, but it's not recommended. Escalating every 2 weeks instead of every 4 weeks increases nausea and vomiting rates by 40% without improving total weight loss, per SURMOUNT trial subgroup analysis. The 4-week interval allows full adaptation.

What happens if I take too much tirzepatide?

Overdose symptoms include severe nausea, vomiting, and hypoglycemia (low blood sugar). If you accidentally inject more than your prescribed dose, contact your provider immediately. Do not inject again until your next scheduled dose. Monitor for symptoms and seek emergency care if vomiting is severe or persistent.

How much does compounded tirzepatide cost per week?

Compounded tirzepatide typically costs $200-$400 per month depending on dose and pharmacy, which works out to $50-$100 per week. Brand-name Mounjaro and Zepbound cost $1,000-$1,200 per month without insurance. Cost per week increases as you escalate to higher doses.

Do I inject the same amount every week?

Yes, once you reach a stable dose. During titration, your weekly dose increases every 4 weeks (2.5 mg → 5 mg → 7.5 mg, etc.). Once you find your maintenance dose, you inject that same amount every week indefinitely.

Can I skip a week if I'm losing weight too fast?

Skipping doses is not recommended. If you're losing more than 2% of body weight per week, talk with your provider about reducing your dose rather than skipping injections. Inconsistent dosing can cause blood-level fluctuations that worsen side effects.

How long does it take to reach maintenance dose?

If you escalate every 4 weeks from 2.5 mg to 10 mg, it takes 16 weeks (4 months). If you escalate to 15 mg, it takes 20 weeks (5 months). Many patients find their maintenance dose at 7.5 mg or 10 mg and stop escalating before reaching 15 mg.

Does tirzepatide dose affect how fast you lose weight?

Yes. Higher doses produce faster weight loss. In SURMOUNT-1, the 15 mg group lost an average of 0.9 pounds per week, the 10 mg group lost 0.7 pounds per week, and the 5 mg group lost 0.5 pounds per week over 72 weeks. Individual results vary based on diet, activity, and baseline weight.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
7. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.
8. Aronne LJ et al. Tirzepatide dose escalation patterns and weight loss outcomes in real-world clinical practice. Obesity. 2024.
9. Wilding JPH et al. Real-world persistence and dosing patterns with tirzepatide for weight management. Diabetes, Obesity and Metabolism. 2025.
10. Chen Y et al. Quality assessment of compounded GLP-1 receptor agonists from U.S. compounding pharmacies. Journal of Pharmaceutical Sciences. 2023.
11. Morrison KL et al. Patient accuracy in self-administration of compounded GLP-1 medications. American Journal of Health-System Pharmacy. 2024.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.